Home » Stocks » NAVB

Navidea Biopharmaceuticals, Inc. (NAVB)

Stock Price: $1.76 USD -0.08 (-4.35%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 51.08M
Revenue (ttm) 882,478
Net Income (ttm) -11.68M
Shares Out 28.07M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $1.76
Previous Close $1.84
Change ($) -0.08
Change (%) -4.35%
Day's Open 1.84
Day's Range 1.74 - 1.83
Day's Volume 24,888
52-Week Range 1.46 - 5.02

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

6 days ago - Business Wire

The FDA has granted Navidea Biopharmaceuticals Inc's (NYSE: NAVB) request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis and advancement to the Phase 3 trial...

1 week ago - Benzinga

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

1 week ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

1 month ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

2 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

2 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

2 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

2 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

2 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

3 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

4 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

4 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

4 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

4 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

5 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

6 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

6 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

8 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

8 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

8 months ago - Business Wire

Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

9 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

9 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

9 months ago - Business Wire

Navidea Biopharmaceuticals: Too Many Risks Involved

10 months ago - Seeking Alpha

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

10 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunoth...

10 months ago - Business Wire

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunothe...

11 months ago - Business Wire

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunothe...

11 months ago - Business Wire

Investors need to pay close attention to Navidea Biopharmaceuticals (NAVB) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Retail sales surging 18% in May fared well with the markets this morning, but with growing concerns over a Coronavirus resurgence, it's clear that volatility is just around the corner. We've utilized ou...

Other stocks mentioned: ARCB, ECOR, FLNT, GRUB
1 year ago - Forbes

DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic ag...

1 year ago - GlobeNewsWire

  Live Video Moderated Discussion with CEO, Jed Latkin, to be Held on Tuesday, June 16th, at 2:00 PM ET, Immediately Followed by an Interactive Q&A Session

1 year ago - GlobeNewsWire

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts...

Other stocks mentioned: BLNK, LQDA, SVRA
1 year ago - Forbes

DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precisi...

1 year ago - GlobeNewsWire

Navidea Biopharmaceuticals Inc. (NYSE: NAVB) shares more than doubled to close out the week after the company provided an update from its midstage study in patients with active rheumatoid arthritis (RA).

1 year ago - 24/7 Wall Street

Shares of Navidea Biopharmaceuticals Inc. NAVB, -1.55% more than doubled in very active premarket trading Friday, after the company provided upbeat data on an ongoing phase 2 trial of its treatment for ...

1 year ago - Market Watch

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Navidea Biopharmaceuticals' (NAVB) CEO Jed Latkin on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

For real-time updates on NAVB, beat the news and login or try Benzinga Pro. Biotechnology company that specializes in precision medicine, Navidea Biopharmaceuticals Inc (NYSE: NAVB) today had a large op...

2 years ago - Benzinga

Navidea Biopharmaceuticals (NAVB) CEO Jed Latkin on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET... [Read more...]

Industry
Biotechnology
IPO Date
Nov 10, 1992
CEO
Jed Latkin
Employees
13
Stock Exchange
NYSEAMERICAN
Ticker Symbol
NAVB
Full Company Profile

Financial Performance

In 2020, NAVB's revenue was $915,013, an increase of 39.10% compared to the previous year's $657,826. Losses were -$10.72 million, -2.07% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for NAVB stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 326.14% from the latest price.

Price Target
$7.50
(326.14% upside)
Analyst Consensus: Buy